Loading...
Market
Alnylam's revenue from Vutrisiran in first year post-approval?
5
Resolution / Starting Odds
Less than $500 million • 33%
$500 million to $1 billion • 33%
More than $1 billion • 33%
Alnylam's financial statements and earnings reports
Story
Alnylam's Vutrisiran Shows Positive Results in Phase 3 Heart Disease Study, Stock Surges 30%
Jun 24, 2024, 11:15 AM
Alnylam Pharmaceuticals announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, a treatment for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). The late-stage study achieved statistical significance on primary and all secondary endpoints in both overall and monotherapy populations. Vutrisiran demonstrated a reduction in the risk of death and recurrent cardiovascular complications. This success likely paves the way for vutrisiran to become the first RNA silencing therapy on the market for ATTR amyloidosis with cardiomyopathy. The positive results have also led to a significant increase in Alnylam's stock price, which surged by 30%.
View original story
Similar markets
Exceeds $1 billion in sales • 25%
Between $500 million and $1 billion in sales • 25%
Between $100 million and $500 million in sales • 25%
Less than $100 million in sales • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Market leader • 33%
Second place • 33%
Third place or lower • 33%
Yes • 50%
No • 50%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Below $500M • 33%
$500M - $1B • 33%
Above $1B • 34%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 33%
$500 million to $1 billion • 34%
More than $1 billion • 33%
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%